TMG, NR and Pterostilbene: The Human Research Behind Each Longevity+ Ingredient

NovusDNA Longevity+ combines four active ingredients at transparent, fully disclosed doses: nicotinamide riboside chloride (NR-CL) at 250 mg, trimethylglycine (TMG) at 175 mg, pterostilbene at 75 mg, and piperine at 2.5 mg, delivered in a single daily capsule.

When reviewing the longevity+ ingredients research, an honest appraisal must acknowledge that the published human clinical trial literature is not equally mature for every single component. NR possesses the largest, most consistent human clinical trial base of any modern NAD+ precursor. TMG's role in homocysteine reduction and methyl donation represents one of the most repeatedly verified findings in metabolic nutrition, while its athletic performance data is newer and considerably more mixed. Pterostilbene exhibits superior pharmacokinetic bioavailability compared to resveratrol, but its direct human clinical trial record is smaller and less conclusive. Piperine acts as an absorption enhancer with robust documentation, primarily derived from clinical studies on polyphenol uptake.

Understanding what the scientific studies actually evaluated provides clear insight into why these specific nutrients were selected together and how they function in human biology.

Benchmarking the UK Longevity Landscape: How Top Brands Formulate

To contextualise how multi-ingredient longevity formulas are developed in the United Kingdom, it is useful to assess the formulation strategies of the leading category players:

• Tru Niagen: As the pioneer of commercial nicotinamide riboside, Tru Niagen focuses exclusively on a single active ingredient, delivering 300 mg of patented NIAGEN per capsule. Their strategy focuses entirely on intracellular NAD+ replenishment. However, this monotherapy leaves methyl donor depletion unaddressed and includes no sirtuin-activating polyphenols.

• DoNotAge: A major UK longevity brand that offers single-ingredient powders and capsules, including pure TMG, NMN, and resveratrol. DoNotAge provides consumers with the flexibility to dose individual compounds at multi-gram levels matching specific isolated trials. The practical downside is that consumers must purchase, manage, and consume multiple separate jars daily to build a comprehensive routine.

• Elysium Health (Basis): Elysium pairs an NAD+ precursor with a sirtuin activator by combining 250 mg of nicotinamide riboside with 50 mg of pterostilbene. This established the blueprint for combining cellular energy support with antioxidant polyphenols. However, Elysium omits a dedicated methyl donor like TMG to support the downstream clearance of nicotinamide.

NovusDNA addresses these individual limitations by balancing cellular energy precursors, methyl pool protection, sirtuin activation, and absorption enhancement in a single, transparent formula.

Why the Evidence Is Not Equally Strong for Each Ingredient

Not every nutrient in a combined dietary formula carries an identical volume of published clinical trials. Presenting preliminary laboratory findings as equivalent to large-scale human outcome data misleads consumers.

The summary below illustrates the relative maturity of the human evidence base supporting each active ingredient in Longevity+:

• NR-CL (Nicotinamide Riboside Chloride): 250 mg per capsule. Key clinical trials: Trammell 2016, Conze 2019, Martens 2018. Evidence maturity: exceptionally high; multiple published human pharmacokinetic and dose-response trials.

• TMG (Trimethylglycine / Betaine): 175 mg per capsule. Key clinical trials: multiple randomised controlled trials on plasma homocysteine, 2024 strength meta-analysis. Evidence maturity: long established for remethylation; emerging and specific for physical performance.

• Pterostilbene: 75 mg per capsule. Key clinical trials: Kapetanovic 2011, Riche 2013, Riche 2014. Evidence maturity: strong pharmacokinetic and safety profiles; limited and mixed clinical efficacy trials.

• Piperine: 2.5 mg per capsule. Key clinical trials: Shoba 1998, Wightman 2014. Evidence maturity: thoroughly documented as a botanical bioavailability enhancer across human pharmacokinetic models.

It is equally important to understand why some ingredient amounts in a multi-nutrient formula differ from the standalone doses used in isolated clinical trials. Research studies frequently administer high doses of an isolated molecule to evaluate a single physiological endpoint, such as acute plasma homocysteine reduction or supranormal strength output.

Longevity+ follows a distinct formulation brief: the four active compounds are balanced to work together in a single daily capsule, providing multi-pathway support rather than targeting one isolated biomarker at the expense of capsule size and tolerability. Every milligram is printed on the supplement facts label, avoiding hidden proprietary blends.

TMG (Trimethylglycine): The Most Established Evidence in the Formula

Trimethylglycine, commonly referred to as betaine, is an organic osmolyte and methyl donor with an extensive history in human nutrition research. The scientific interest in TMG centres on its ability to donate a methyl group to homocysteine via the hepatic enzyme betaine-homocysteine S-methyltransferase (BHMT), converting it into the essential amino acid methionine.

In a landmark randomised controlled trial published in the British Journal of Nutrition, healthy human volunteers receiving 3 g of betaine daily experienced an approximate 10 percent reduction in fasting plasma homocysteine within one week. Participants receiving 6 g daily achieved an approximate 14 percent reduction. This biochemical shift occurred rapidly and was maintained across subsequent dosing cycles. This dose-dependent response has been validated across more than two decades of controlled nutritional trials, making TMG homocysteine research one of the most reliable areas of metabolic science.

Longevity+ contains 175 mg of TMG, which is a fraction of the 3 g to 6 g administered in those standalone biomarker studies. This difference reflects the role TMG plays within the formula: it is included to support baseline physiological methylation when nicotinamide is cleared by the liver, rather than acting as a high-dose therapeutic agent for hyperhomocysteinemia.

A secondary line of research investigates betaine's role in physical performance. A comprehensive systematic review and meta-analysis pooling 17 controlled trials and 317 human participants determined that betaine supplementation of roughly 2.5 g daily for at least one week yielded measurable improvements in lower-body muscular strength.

However, the analysis detected no statistically significant benefit on muscular endurance, cycling sprint power, or maximal aerobic capacity, with notable heterogeneity among individual studies. This represents a nuanced outcome: betaine supports acute force production under specific conditions at multi-gram doses, but it should not be viewed as a blanket athletic performance enhancer.

NR (Nicotinamide Riboside Chloride): The Deepest Human Trial Base

Nicotinamide riboside anchors the Longevity+ formula because it holds the most extensive published clinical dataset among modern NAD+ precursor research UK consumers evaluate. Nicotinamide adenine dinucleotide (NAD+) is a vital coenzyme present in all living cells, required for mitochondrial ATP generation, sirtuin activation, and PARP-mediated DNA repair. Because systemic NAD+ concentrations decline progressively with age, providing bioavailable precursors supports intracellular NAD+ pools.

The first human clinical study, published in Nature Communications in 2016, confirmed that orally administered nicotinamide riboside safely, dose-dependently, and sustainably elevated the circulating blood NAD+ metabolome in healthy adults across single doses of 100 mg, 300 mg, and 1,000 mg.

Following that initial trial, a large, randomised, double-blind, placebo-controlled study evaluating NR chloride specifically, the precise crystalline salt form utilised in Longevity+, monitored 140 healthy overweight adults over eight weeks. The researchers observed robust, dose-dependent increases in whole-blood NAD+:

• A 100 mg daily dose produced an approximate 22 percent rise in circulating NAD+.

• A 300 mg daily dose produced an approximate 51 percent rise in circulating NAD+.

• A 1,000 mg daily dose produced an approximate 142 percent rise in circulating NAD+.

These elevated coenzyme levels remained stable throughout the two-month intervention. The 250 mg dose provided in Longevity+ sits within this clinically validated range, just below the 300 mg study arm.

Further research conducted in healthy middle-aged and older adults administering 500 mg twice daily for six weeks recorded an approximate 60 percent increase in intracellular NAD+ inside peripheral blood mononuclear cells compared to placebo.

While none of these NR human clinical trials directly tracked maximum human lifespan or clinical disease outcomes, they consistently confirm that oral nicotinamide riboside chloride evidence rests on verifiable increases in cellular coenzyme biomarkers. For a detailed comparison of biological mechanisms, review our comprehensive guide to NMN versus NR.

Pterostilbene: Strong Pharmacology, a Thinner Clinical Record

Pterostilbene is a naturally occurring dimethylated analogue of resveratrol, classified chemically as a stilbenoid. The primary scientific justification for using pterostilbene over traditional resveratrol centres on its superior pharmacokinetic profile.

In comparative preclinical models, animal studies have found that the two methoxy groups in pterostilbene confer higher lipophilicity and structural stability. This molecular arrangement allows pterostilbene to achieve roughly 80 percent oral bioavailability, compared to roughly 20 percent for resveratrol, alongside an extended plasma half-life. We examine these bioavailability and enzymatic activation dynamics in our guide to sirtuin-activating supplements.

However, human clinical outcome trials on pterostilbene remain limited. In a prospective, randomised, double-blind safety trial in 80 adults consuming 50 mg or 125 mg twice daily for six to eight weeks, researchers identified no adverse effects on hepatic enzymes, renal function, or markers of glycemic control. This confirmed that the 75 mg daily dose in Longevity+ sits comfortably within established human safety parameters.

In a companion efficacy trial conducted by the same research team, participants taking 125 mg twice daily experienced a statistically significant reduction in blood pressure: systolic readings dropped by approximately 7.8 mmHg and diastolic readings dropped by approximately 7.3 mmHg relative to placebo.

However, the researchers also observed an unexpected increase in circulating LDL cholesterol of roughly 25 mg/dL in that high-dose group. Interestingly, this lipid elevation was absent when pterostilbene was co-administered with grape extract.

This finding illustrates that pterostilbene human studies show a genuine physiological impact, but the clinical evidence is less extensive and more mixed than that of NR. Dose, timing, and companion nutrients play a defining role in how the compound behaves in human physiology.

Piperine: A Bioavailability Enhancer, Not a Primary Active Compound

Piperine, an alkaloid extracted from black pepper (Piper nigrum), is not included in Longevity+ to provide an isolated health benefit. Its purpose is to function as a botanical bioavailability enhancer, optimising the uptake and retention of accompanying polyphenols.

The landmark human trial evaluating this mechanism, published in Planta Medica in 1998, administered 2 g of curcumin alone or in combination with 20 mg of piperine to healthy human volunteers. The co-administration of piperine increased the serum bioavailability of curcumin by an extraordinary 2,000 percent, outperforming the absorption rates observed in animal models.

The primary mechanism behind this enhancement is piperine's ability to temporarily inhibit glucuronidation, a phase II detoxification pathway in the small intestine and liver that normally adds a glucuronide molecule to polyphenols, facilitating their rapid excretion.

By modulating this enzymatic breakdown, piperine allows co-ingested botanicals to circulate in the bloodstream longer. Subsequent randomised, double-blind crossover human trials have evaluated piperine alongside resveratrol, a structural relative of pterostilbene, demonstrating positive modulation of cerebral blood flow.

Longevity+ provides 2.5 mg of piperine per serving. This is scaled down from the 20 mg reference dose used in high-volume curcumin studies to offer gentle enzymatic modulation appropriate for daily use, while avoiding gastrointestinal irritation or unwanted pharmaceutical interactions.

The Biochemical Rationale: Methylation and the NAD+ Salvage Pathway

The inclusion of TMG alongside NR-CL addresses a crucial metabolic pathway that is often overlooked in single-ingredient longevity supplements:

1. NAD+ Biosynthesis and Consumption: When oral NR enters the cell, it is converted via nicotinamide riboside kinase (NRK) into nicotinamide mononucleotide (NMN), which is subsequently converted into NAD+. Sirtuins and PARP enzymes consume this NAD+, cleaving off the riboside group and releasing free nicotinamide (NAM) as a metabolic byproduct.

2. The Methylation Bottleneck: To prevent excessive intracellular concentrations of free nicotinamide, which can inhibit sirtuin activity, the body clears excess NAM via the hepatic enzyme nicotinamide N-methyltransferase (NNMT). This enzyme attaches a methyl group to NAM to produce N-methylnicotinamide, which is safely excreted in urine.

3. Methyl Pool Depletion: This clearance pathway consumes S-adenosylmethionine (SAMe), the body's primary methyl donor. High daily doses of an NAD+ precursor can place sustained demand on cellular methyl pools, potentially driving up plasma homocysteine if methyl reserves are low.

4. Remethylation via TMG: Supplying trimethylglycine provides the hepatic cells with fresh methyl groups, allowing homocysteine to be converted back into methionine and replenishing SAMe reserves.

This functional relationship highlights the value of betaine and methylation research in modern longevity formulation. Combining a methyl donor with an NAD+ precursor supports cellular energy production while helping preserve methyl reserves.

Assessing these four ingredients together provides a clear picture of their combined utility. NR has the most consistent clinical trial backing, TMG's homocysteine-regulating mechanisms are well documented, piperine's bioavailability enhancement is established in human pharmacokinetic trials, and pterostilbene offers favorable pharmacokinetics alongside early-stage human efficacy data.

No published clinical trial has tested this specific four-ingredient combination at Longevity+'s exact dosages, and it is important to state that plainly. What the formula does offer is a transparent, research-informed blend of ingredients at disclosed milligram amounts, rather than an unverified proprietary matrix.

For additional details on how this formula was developed, explore our Longevity+ ingredients and benefits overview. To understand how this supplement integrates into a wider daily wellness routine, consult our guide for anyone thinking about trying it.

FAQ

Which ingredient in Longevity+ has the strongest human clinical trial evidence?

Nicotinamide riboside chloride (NR-CL) has the largest and most consistent body of published human clinical data. Multiple human trials confirm that oral NR safely, sustainably, and dose-dependently increases whole-blood and cellular NAD+ concentrations. While TMG has decades of clinical data regarding homocysteine regulation, NR has been evaluated across a wider range of modern cellular ageing and NAD+ metabolome trials.

Does the published TMG homocysteine research apply directly to the dose in Longevity+?

The clinical trials that established betaine's ability to lower elevated plasma homocysteine typically administered 3 g to 6 g daily. Longevity+ contains 175 mg of TMG. It is included to support natural methylation processes and aid the clearance of nicotinamide byproducts, rather than to serve as a high-dose clinical treatment for severe hyperhomocysteinemia.

Why does pterostilbene have fewer clinical trials than traditional resveratrol?

Resveratrol has been studied for decades in academic medicine, giving it an older, larger clinical footprint. Pterostilbene emerged as a compound of interest more recently, largely because researchers sought an alternative with better oral bioavailability and metabolic stability. Consequently, human safety and pharmacokinetic trials were established first, while large-scale human efficacy trials remain in development.

What is the exact function of piperine in the Longevity+ capsule?

Piperine serves as a botanical bioavailability enhancer rather than a primary longevity compound. By temporarily moderating phase II hepatic and intestinal glucuronidation, it helps protect companion botanicals like pterostilbene from rapid excretion, improving their circulation and uptake in peripheral tissues.

Has the full four-ingredient Longevity+ formula been evaluated in a dedicated human clinical trial?

No. Each of the four active ingredients possesses its own published human clinical trial history, but the complete four-part formulation has not been tested in a single clinical trial. This is standard across multi-ingredient dietary supplements. To maintain transparency, NovusDNA displays the exact milligram dose of every compound on the label, allowing consumers to cross-reference each ingredient with the clinical literature.

Every dose referenced throughout this analysis matches the physical facts panel printed on the bottle. You can review the complete ingredient profile directly on the NovusDNA Longevity+ product page to evaluate how each active ingredient aligns with the published research.